Levetiracetam Hikma (Levetiracetam)

Levetiracetam is an antiepileptic medication used to control various seizure types.

• Partial seizures: reduces the frequency of focal seizures in patients with epilepsy
• Generalized tonic‑clonic seizures: helps prevent convulsive episodes in adults and children
• Myoclonic seizures: decreases the occurrence of sudden muscle jerks associated with juvenile myoclonic epilepsy

• Levetiracetam binds to the synaptic vesicle protein SV2A, modulating neurotransmitter release and stabilizing neuronal membranes. This interaction reduces abnormal neuronal firing and excitability, thereby decreasing the likelihood of seizure propagation across the central nervous system.

Levetiracetam may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness: mild to moderate sensation of light‑headedness
• Fatigue: generalized tiredness or lack of energy
• Somnolence: increased sleepiness or drowsiness
• Headache: mild to moderate cranial pain
• Irritability: mood changes or increased agitation
• Nausea: upset stomach or feeling of queasiness

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction with rash, swelling, or breathing difficulty
• Stevens‑Johnson syndrome: rare skin disorder with blistering and detachment
• Blood dyscrasias: abnormal blood counts such as neutropenia or thrombocytopenia
• Suicidal ideation: emergence of thoughts of self‑harm or depression
• Severe skin rash: widespread rash that may progress to toxic epidermal necrolysis
• Respiratory depression: marked reduction in breathing effort, especially with concomitant depressants

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Renal impairment: adjust dose based on creatinine clearance and monitor renal function
• Hepatic impairment: use with caution and observe for increased plasma concentrations
• Pregnancy: limited data; prescribe only if potential benefit justifies potential risk to the fetus
• Concomitant CNS depressants: may enhance sedation or respiratory depression; monitor closely
• Behavioral changes: observe for mood swings, aggression, or suicidal thoughts during treatment
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake

Levetiracetam has a low potential for drug‑drug interactions, but certain combinations require attention.

Major Interactions (Avoid)

• Phenobarbital: may lower levetiracetam plasma levels, reducing efficacy
• Carbamazepine: can decrease levetiracetam concentrations, potentially leading to breakthrough seizures

Moderate Interactions (Monitor Closely)

• Other antiepileptic drugs: monitor seizure control and adjust doses as needed
• Sedative agents (benzodiazepines, alcohol): may increase central nervous system depression
• Renal excretion inhibitors (e.g., probenecid): may raise levetiracetam levels, requiring observation
• Live vaccines: consider timing, as immunomodulation could affect vaccine response